Merck execs pull down $36M in pay

Just in time to be overshadowed by news of the company merger with Schering-Plough, Merck filed its SEC disclosure on executive pay. The gist? Top managers snared a total of $36 million in compensation for 2008, plus use of the corporate jet. All of them reaped cash bonuses--ranging from $563,767 and $2.2 million--as part of their packages even though two of them delivered "below-target performance," BNet Pharma reports.

Here are the numbers, man by man. And yes, they are all men:

  • CEO Richard Clark (photo) got $19.9 million, total, up a smidge from 2007's $19.6 million.
  • CFO Peter Kellogg pulled down $3.8 million, more than twice his 2007 package of $1.2 million.
  • R&D chief Peter Kim earned $4.2 million, down from $6.2 million; this year's amount includes a cash bonus of more than $875,000.
  • Global Health President Kenneth Frazier nabbed $5.5 million, down just a bit from $5.6 million in 2007; his cash bonus was more than $986,000.
  • General Counsel Bruce Kuhlik got $2.6 million.

The executive millions were handed out for a year when Merck's stock dropped by half and, excluding the effect of last year's $4.5 billion Vioxx settlement, net profits fell by 49 percent, BNet points out. Sales fell by 3 percent to $6 billion. And during 2008, the company announced 8,400 job cuts.

For 2009, though, Merck will be able to boast of big growth, thanks to the Schering-Plough deal. We'll have to wait and see how that affects Clark's paycheck.

- read the BNet post
- see Merck's filing with the SEC

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.